J&J’s ponesimiod tops Aubagio in head-to-head MS trial

market-leading Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus(ocrelizumab) also making strong headway in the market. ... There is also a looming threat of generic competition to Gilenya and Tecfidera, which could make it harder

Merck takes evobrutinib for MS into phase 3, on mixed data

If successful, Merck will have a chance to bring forward a new-mechanism therapy for relapsing MS that will compete with blockbuster oral drugs such as Biogen’s Tecfidera (dimethyl fumarate), ... It will also have to contend with newer drugs like

Tecfidera successor’s side-effect profile boosts Biogen

One of the biggest issues is that these newer treatments don’t cause the gastrointestinal side-effects frequently seen in patients taking Tecfidera. ... Overall discontinuation rates were 1.6% for Vumerity and 6.0% for Tecfidera.

Biogen grows in Q2, but Spinraza performance a concern

The performance was thanks largely to its under-pressure multiple sclerosis (MS) franchise, where combined sales of Tecfidera, Avonex, Plegridy and Tysabri totalled $2.2bn. ... palsy. One big binary decision awaiting the firm is a challenge

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]